Development of novel nucleic acid therapy aimed at directly controlling liver fibrosis
Currently, no drugs directly treat liver fibrosis. Previously, we have shown that treatment with miR-29a-3p improved liver fibrosis in a mouse model. To investigate the effectiveness of nucleic acid therapy at a lower dose, a modified nucleic acid was prepared based on miR-29a-3p. The original micro...
Saved in:
Main Authors: | Tomohiro Umezu, Masakatsu Takanashi, Koji Fujita, Akio Ishikawa, Yuichirou Harada, Yoshinari Matsumoto, Masahiko Kuroda, Yoshiki Murakami |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253124003251 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01) -
Nucleic acid therapeutics: Past, present, and future
by: Sajid Naeem, et al.
Published: (2025-03-01) -
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01) -
Unveiling sequence-agnostic mixed-chemical modification patterns for splice-switching oligonucleotides using the NATURA platform
by: Tommaso Tabaglio, et al.
Published: (2025-03-01) -
Genomic Profiling of Liver Cancer
by: Ju-Seog Lee
Published: (2013-12-01)